All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Roche, Qyuns Therapeutics license respiratory disease bispecific QX031N, $75M upfront, $995M milestones
Licensing deal, respiratory disease, bispecific antibody, milestone payments - Read more

Boehringer Ingelheim, Kyowa Kirin license preclinical autoimmune small molecule for €640M ($743M) deal
Licensing deal, autoimmune, small molecule, milestone payments - Read more

CSL Seqirus partners with Saudi Arabia on flu vaccine supply and local production, financial terms undisclosed
Manufacturing agreement, vaccine, infectious disease, pandemic preparedness - Read more

Wheeler Bio, Mitsubishi Corporation partner to accelerate Asia-Pacific business development with Series A-1 investment
Strategic partnership, biomanufacturing, antibody, equity investment - Read more

Everest Medicines, Visara license ophthalmic bispecific VIS-101, $7M upfront, $89M milestones
Licensing deal, ophthalmic, bispecific antibody, milestone payments - Read more

Piramal Pharma Solutions, IntoCell formalize ADC development partnership to expand payload-linker platform capabilities
Manufacturing agreement, antibody-drug conjugate, licensing deal, bioconjugate development - Read more

InSysBio, BeOne Medicines collaborate on QSP modeling for GPC3 x 4-1BB bispecific antibody BGB-B2033
Research collaboration, oncology, antibody, drug discovery - Read more

4DMT, Otsuka license 4D-150 for Asia-Pacific retinal diseases, $85M upfront, $336M milestones
Licensing deal, gene therapy, ophthalmology, milestone payments, royalties - Read more

PRESENTED BY SCIENCE 2 SALES
Your BD reps should be focused on closing (not cold calling) - that’s where we can help.

You’re not paying your highly qualified BD reps to knock on doors and cold call - they’re expensive and you want them focused on real opportunities.

That’s where Science 2 Sales comes in - we’ll do all the:

• Cold calling ☎️

• Cold email 📧

• Linkedin Outreach 💼

• AND impactful LinkedIn content for your exec teams + SMEs

That actually drives pipeline. We offer a 30 day money back guarantee on your first month - that’s how strongly we believe if what we offer.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Gilead ends Ph1 trial of GS-1219, selects GS-3242 as twice-yearly partner for lenacapavir HIV treatment
Small molecule, infectious disease, integrase inhibitor, HIV, capsid inhibitor, combination therapy - Read more

Avobis Bio's AVB-114 shows 45.8% remission rate in Ph2 trial for Crohn's disease perianal fistulas
Cell therapy, autoimmune, implantable cell therapy, Crohn's disease, perianal fistula - Read more

AstraZeneca's gefurulimab (ALXN1720) meets Ph3 endpoints for generalized myasthenia gravis targeting complement protein C5
Protein therapy, autoimmune, nanobody, generalized myasthenia gravis, complement inhibition, C5 protein - Read more

Tectonic Therapeutic reports positive Ph1b results for TX45 in Group 2 pulmonary hypertension in heart failure with reduced ejection fraction
Protein therapy, cardiovascular, fusion protein, pulmonary hypertension, heart failure - Read more

Wave Life Sciences reports positive Ph1 biomarker data for WVE-007 targeting INHBE in obesity treatment
RNA therapy, metabolic, siRNA, obesity, INHBE target - Read more

THE GOOD
Earnings & Finances

Alnylam's Amvuttra beats Q3 estimates with $685M sales, driving $275M guidance increase
RNAi therapy, rare disease, financial, revenue impact - Read more

Merck & Co.'s adult pneumococcal vaccine Capvaxive hits $244M Q3 sales amid industry vaccine decline
Vaccine, infectious disease, financial, competitive - Read more

Biogen raises sales outlook as legacy MS drugs stay resilient while new neurological launches gain momentum
Monoclonal antibody, neurological, financial, strategic - Read more

Eli Lilly raises revenue forecasts as obesity drug tirzepatide becomes world's best-selling medication
GLP-1 receptor agonist, metabolic disease, revenue impact, major transaction - Read more

THE GOOD
Fundraises

Evommune raises $159M IPO, inflammation biotech developing chronic urticaria treatments
Inflammation, small molecule, clinical-stage, autoimmune - Read more

Cunde Medical raises undisclosed Series A, mRNA-DC tumor vaccines and cell therapy
Cell therapy, mRNA technology, oncology, personalized medicine - Read more

CytoCares raises undisclosed A++ round, tri-specific TCE platform for autoimmune diseases
Tri-specific antibody, autoimmune, SLE, clinical-stage - Read more

Oculis raises $110M public offering, accelerating Privosegtor development for optic neuroprotection
Ophthalmology, neurological, neuroprotective, clinical-stage - Read more

Evaxion raises $7.2M equity funding, AI-powered vaccine development platform
AI/ML platform, vaccines, clinical-stage, platform technology - Read more

Longwood Biopharmaceuticals raises hundreds of millions RMB Series B+, innovative drug development
Autoimmune, antiviral, small molecule, clinical-stage - Read more

Seres Therapeutics receives $3.6M CARB-X grant for SER-155 liquid formulation development
Live biotherapeutics, infectious disease, microbiome therapy, clinical-stage - Read more

iOrganBio raises $2M funding, AI-powered platform for cell and organoid manufacturing
Cell therapy, AI/ML platform, organoid technology, platform-enabled - Read more

Tubulis raises $401M Series C, pushing boundaries of antibody-drug conjugates
Antibody-drug conjugates, oncology, clinical-stage, platform technology - Read more [Paywall]

Savara raises $75M royalty funding, supports MOLBREEVI launch for autoimmune PAP
Rare disease, respiratory, autoimmune, clinical-stage - Read more

THE GOOD
Mergers & Acquisitions

Novo Nordisk drops $6.5B bid for obesity drug-maker Metsera, sparking bidding war with original acquirer Pfizer 
GLP-1 receptor agonist, obesity, strategic, major transaction - Read more

THE GOOD
Product Launches

ProImmune launches ProVE SL monomers for enhanced CD8+ T cell detection across 50+ HLA alleles
Immunotherapy reagents, oncology, operational, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Eli Lilly halts Ph2 development of LY3857210 P2X7 inhibitor for chronic pain indications
Small molecule, pain, P2X7 inhibitor, osteoarthritis, diabetic neuropathic pain - Read more

Takeda discontinues TAK-341 (alpha-synuclein antibody) for multiple system atrophy after Ph2 trial failure
Antibody, neurological, monoclonal antibody, multiple system atrophy, alpha-synuclein target - Read more

Ventus Therapeutics terminates VENT-02 NLRP3 inhibitor Ph2 trial in Parkinson's disease after enrolling 29 patients
Small molecule, neurological, NLRP3 inhibitor, Parkinson's disease, neuroinflammation - Read more [Paywall]

THE BAD
Earnings & Finances

Bristol Myers Squibb’s Cobenfy misses Q3 estimates at $43M amid challenges changing schizophrenia prescribing habits
Small molecule, neurological, financial, operational - Read more

Merck's Gardasil HPV vaccine sales plummet 25% globally amid declining US and China demand
Vaccine, infectious disease, financial, operational - Read more

Takeda cuts full-year guidance as Vyvanse generic competition drives 45% sales decline, shares fall 8%
Small molecule, neurological, financial, strategic, revenue impact - Read more

THE BAD
Layoffs

Sensei abandons sole clinical-stage cancer drug solnerstotug, plans layoffs amid funding challenges
Monoclonal antibody, oncology, operational, financial - Read more

THE BAD
Strategic Plans

Bristol Myers Squibb drops two clinical programs from Mirati acquisition and Exscientia partnership in pipeline restructuring
Small molecule, oncology, strategic, operational - Read more

THE UGLY
Regulatory

FDA places clinical hold on Intellia Therapeutics' CRISPR gene therapy trials after life-threatening liver toxicity event
Gene therapy, rare disease, regulatory, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here